Nanoparticulate drugs and vaccines: Breakthroughs and bottlenecks of repurposing in breast cancer

Kumbhar, Popat; Kole, Kapil; KHADAKE, Varsha; MARALE, Pradnya; Manjappa, Arehalli S.; Nadaf, Sameer J.; Jadhav, Rajendra Dattu; Patil, Ajit B.; Singh, Sachin Kumar; Dua, Kamal; Jha, Niraj Kumar; Disouza, John; Patravale, Vandana

doi:10.1016/j.jconrel.2022.07.039

Cited by 13 publications

(10 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The resultant IC 50 values were as low as 5.18 and 6.7 μM in MDA-MB 231 and MCF-7 cells, respectively. The respective IC 50 values for free drugs were 11.9 and 12.2 μM …”

Section: Polymeric Platformsmentioning

confidence: 98%

“…The respective IC 50 values for free drugs were 11.9 and 12.2 μM. 25 Micelles. Amphiphilic polymers self-assembled into nanosized particles are called Micelles, upon reaching critical micelle concentration.…”

Section: Drug Deliverymentioning

confidence: 99%

“…24 Additionally, they help improve permeability, cargo loading efficiency, circulation half-life, stability, and drug release kinetics. 25 Liposomes have been widely used as nanocarriers to transfer anticancer drugs (derivatives of Doxorubicin (DOX), Paclitaxel (PTX) and Platinum based anticancer drugs) into tumor tissues. 26 These favorable features have rendered the use of cationic liposomes as successful carriers for metformin in low-doses (antidiabetic drug) against breast cancer.…”

Section: Drug Deliverymentioning

confidence: 99%

“…Liposomes have been used as both passive targeting and active targeting agents in cancer therapy . Additionally, they help improve permeability, cargo loading efficiency, circulation half-life, stability, and drug release kinetics . Liposomes have been widely used as nanocarriers to transfer anticancer drugs (derivatives of Doxorubicin (DOX), Paclitaxel (PTX) and Platinum based anticancer drugs) into tumor tissues …”

Section: Available Nanoplatforms For Repurposed Drug Deliverymentioning

confidence: 99%

See 3 more Smart Citations

Ameliorating Old Drugs with New Tricks in the Nano Realms

Choudhury,

Ghosh

2024

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

Cancer is conventionally treated by chemotherapy, radiotherapy, or surgery. The urgent need to look for alternative therapeutic strategies reflects many loopholes. Developing a drug, however, is both time-consuming and expensive. Therefore, repurposing a licensed drug along with a means to take care of the limitations can become a very sustainable approach in cancer therapy. To further intensify these responses, nanotechnology would be useful to enhance the drug’s delivery and retention while reducing toxicity. In this review, we explore the complicated association of cancer and drug repurposing and summarize recent advances in nanomaterial-based drug repurposing approaches.

show abstract

“…The resultant IC 50 values were as low as 5.18 and 6.7 μM in MDA-MB 231 and MCF-7 cells, respectively. The respective IC 50 values for free drugs were 11.9 and 12.2 μM …”

Section: Polymeric Platformsmentioning

confidence: 98%

Section: Drug Deliverymentioning

confidence: 99%

Section: Drug Deliverymentioning

confidence: 99%

Section: Available Nanoplatforms For Repurposed Drug Deliverymentioning

confidence: 99%

See 2 more Smart Citations

Ameliorating Old Drugs with New Tricks in the Nano Realms

Choudhury,

Ghosh

2024

ACS Appl. Nano Mater.

View full text Add to dashboard Cite

show abstract

“…Various non-oncology drugs including metformin (MFN), tadalafil (TDL), ketoconazole (KCZ), simvastatin (SVN), verapamil (VPL), and disulfiram (DSR), etc. have displayed potential anticancer activities against sorts of cancers including lung, liver, breast and melanoma [15][16][17][18][19][20]. Therefore, in the present research efforts have been made to preliminarily ascertain the in vitro and in silico anticancer activities of various non-oncology drug categories against human osteosarcoma cells, both singly and in combination.…”

Section: Introductionmentioning

confidence: 99%

In vitro, in silico and in vivo screening of non-oncology drugs for repurposing in osteosarcoma

DESAI¹,

MANJAPPA²,

KHULBE³

et al. 2023

jrp

View full text Add to dashboard Cite

The first-line chemotherapy is associated with chief shortfalls such as non-specific distribution causing severe dose-dependent toxicities and development of tumor resistance. The current preliminary study aimed to identify the safe and effective non-oncology drugs as an alternative to toxic chemotherapeutics to treat osteosarcoma, and overcome new drug's shortage and development challenges. The different category non-oncology drugs (alone and in combinations) were screened for in vitro cytotoxicity behavior via MTT dye reduction assay and cell cycle arresting behavior using flow cytometer against human osteosarcoma (Saos-2 and MG-63) cells. The molecular docking of selected therapeutics was executed against cyclin-dependent kinase 1 (CDK1), cell cycle regulator overexpressed in cancer. The identified combination was further tested for in vivo toxicities in rats at two different doses. The current study revealed niclosamide (NSD), ketoconazole (KCZ), simvastatin (SVN) combination that causes substantial cytotoxicity (IC50 values are in picomoles) at 1:1:3 molar ratio when compared to other molar ratios. This combination has also caused substantial arrest of Saos-2 and MG-63 cells at S and G2/M phase. Additionally, all three drugs demonstrated better interaction with CDK1 indicating anticancer potential via inhibition of CDK1. Furthermore, the in vivo toxicity study revealed no significant changes in hematological and biochemical parameters, body weights of rats, weights of vital organs, daily food and water intake, and general behavior of rats. The obtained preliminary results revealed the potential application of this combination on non-oncology drugs in the safe and effective treatment of osteosarcoma. However, further in-depth studies are required before clinical application.

show abstract